explore -WSS

explore

author：entertainment 2025-09-30 21:57:33 - browse：5

Two people stare at a keyhole in a human head in between them, as the short-haired person on the left holds a key — first opinion coverage from STAT — Adobe

In many ways, psychiatry is still flying blind. People experiencing mental health conditions are prescribed various drugs until one (or a combination) finally works — a painful process that can take years. As a psychiatrist and neuroscientist, I became increasingly impatient and frustrated with this ineffective way of treating patients. This guided the core question behind my research: Can biology explain how people with the same psychiatric disorder respond differently to the same treatment?

Since I first began exploring this question more than a decade ago, mental illness has become a global epidemic. Despite significant efforts, progress in psychiatric drug development has remained disappointingly slow. There have been a few notable approvals in recent years, and a renewal of interest by Big Pharma, following a retreat from psychiatric research in the mid to late 2000s. But the landscape remains predominantly marked by failures and a dry drug development pipeline. Approved drugs follow the same pattern of prescribing via guesswork, with most patients not responding to a given drug. This cycle of trial-and-error drug development producing trial-and-error treatment arises from a simple source: We have not systematized a process for learning from our failures and successes.

Related: A ‘renaissance in neuroscience’ could deliver a fresh crop of psychiatric medicines

For example, take depression: While the rise of selective serotonin reuptake inhibitors (SSRIs) in the 1980s and 1990s seemed to provide a solution, seminal studies in the 2000s exposed fundamental limitations of our treatment options. Antidepressants are widely prescribed, but their efficacy relative to placebo is modest.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： World's first CRISPR

explore

WSS

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

Carbon Health diabetes program, a test of data

David Sabatini, ex

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

Carbon Health diabetes program, a test of data

Ventyx halts psoriasis drug development after lackluster trial results

focus

explore

Related: A ‘renaissance in neuroscience’ could deliver a fresh crop of psychiatric medicines

knowledge

United colonoscopy coverage change 'may cost lives,' doctors say

Does good food count as health care? Study aims to find out

Malaria cases in Florida and Texas: Here’s what you need to know

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

Hepatitis C has a cure — but many Americans still lack access to it

Poor hospice wound care hurts patients and families

Wildfire smoke exposes gaps in outdoor worker protections

Weight loss drug costs may need more research, senator suggests

Continuity nursing helped my family in our darkest PICU moments

CVS, Rite Aid closures threaten to worsen pharmacy deserts

Wikipedia

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

Ransomware attacks on hospitals: Study outlines patient impact

White House drug czar issues call for 'recovery

Medical school prerequisites are outdated

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

Cancer diagnosis changes perspective doctor, former hospital CEO

hotspot

explore

hotspot

Wikipedia